Contrasting Beam Therapeutics (NASDAQ:BEAM) and Mosaic ImmunoEngineering (OTCMKTS:CPMV)

Beam Therapeutics (NASDAQ:BEAM) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Volatility & Risk

Beam Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Earnings & Valuation

This table compares Beam Therapeutics and Mosaic ImmunoEngineering”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$352.57 million	5.85	-$132.53 million	($1.78)	-14.07
Mosaic ImmunoEngineering	N/A	N/A	-$1.01 million	($0.13)	-6.91

Mosaic ImmunoEngineering has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Mosaic ImmunoEngineering, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Beam Therapeutics and Mosaic ImmunoEngineering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	0	7	6	0	2.46
Mosaic ImmunoEngineering	0	0	0	0	N/A

Beam Therapeutics presently has a consensus target price of $44.18, suggesting a potential upside of 76.37%. Given Beam Therapeutics’ higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Mosaic ImmunoEngineering.

Insider and Institutional Ownership

99.7% of Beam Therapeutics shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Beam Therapeutics and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-40.56%	-16.22%	-10.65%
Mosaic ImmunoEngineering	N/A	N/A	-870.03%

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.